Similar Papers

Paper Title
Journal
Date
Author
Ibrutinib—a new standard treatment for relapsed mantle cell lymphoma?
Peter Martin
The Lancet | VOL. 387
Peter MartinPeter Martin
07 Dec 2015
Combined Targeting of Chromatin Modifying Enzymes LSD1, EZH2 and Histone Deacetylases (HDACs) Has Superior Efficacy Against Human Mantle Cell Lymphoma Cells
Warren Fiskus ... Kapil N Bhalla
Blood | VOL. 118
Warren Fiskus, et. al.Warren Fiskus ... Kapil N Bhalla
18 Nov 2011
Combined Epigenetic Therapy with the Novel Histone Methyl Transferase EZH2 Inhibitor 3-Deazaneplanocin and Histone Deacetylase Inhibitor Panobinostat Exerts Synergistic Activity against Human Mantle Cell Lymphoma Cells
Warren Fiskus ... Kapil N Bhalla
Blood | VOL. 112
Warren Fiskus, et. al.Warren Fiskus ... Kapil N Bhalla
16 Nov 2008
New agents for the treatment of lymphoid leukemia and lymphoma: focus on recent FDA approvals.
Andreea Lucia Stancu ... Alexandru Almasan
Discoveries (Craiova, Romania) | VOL. 2
Andreea Lucia Stancu, et. al.Andreea Lucia Stancu ... Alexandru Almasan
31 Mar 2014
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Acute myeloid leukemia with BCL6 and KMT2A dual rearrangements
Qiudan Shen ... Shimin Hu
Blood | VOL. 145
Qiudan Shen, et. al.Qiudan Shen ... Shimin Hu
06 Feb 2025
The dark zone of CNS relapse in DLBCL
Kieron Dunleavy
Blood | VOL. 145
Kieron DunleavyKieron Dunleavy
06 Feb 2025
Impact of new medications on the treatment of Immune TTP.
Marie Scully ... William A Lester
Blood | VOL. -
Marie Scully, et. al.Marie Scully ... William A Lester
06 Feb 2025
No exit: targeting RNA export in T-cell malignancy
Katherine L B Borden
Blood | VOL. 145
Katherine L B BordenKatherine L B Borden
06 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.